Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Occurrence of atrial fibrillation in first-degree relatives increases AF risk factors

Occurrence of atrial fibrillation in first-degree relatives increases AF risk factors

Dialysis patients at elevated risk for sudden cardiac death: Study

Dialysis patients at elevated risk for sudden cardiac death: Study

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack

Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack

CorMatrix receives $2.3 million grants under QTDP program to advance ECM technology

CorMatrix receives $2.3 million grants under QTDP program to advance ECM technology

Stereotaxis receives $1.5 million in grants under QTDP program

Stereotaxis receives $1.5 million in grants under QTDP program

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

AtriCure third quarter revenue increases $1.2 million to $14.5 million

AtriCure third quarter revenue increases $1.2 million to $14.5 million

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Health Canada approves PRADAX for preventing stroke in AF patients

Health Canada approves PRADAX for preventing stroke in AF patients

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Coherex achieves two milestones in structural heart disease field

Coherex achieves two milestones in structural heart disease field

ResMed third quarter revenue increases 17% to $282.0 million

ResMed third quarter revenue increases 17% to $282.0 million

CCS presents new 2010 Atrial Fibrillation Guidelines

CCS presents new 2010 Atrial Fibrillation Guidelines

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.